TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy Part 2 will dose ~150 patients with TLC590, bupivacaine, or placeboPrimary endpoint: AUC0-72 on numerical pain rating scaleEnrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA...

TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 14, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...

TLC Announces Phase I/II Full Enrollment in Hernia Repair Surgery and Phase II Initiation in Bunionectomy of TLC590 for Postsurgical Pain TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...